Recommendations for Measuring HIV Reservoir Size in Cure-directed Clinical Trials

Overview

Journal Nat Med

Specialties General Medicine
Molecular Biology

Date 2020 Sep 8

PMID 32895573

Citations 66

Authors

Mohamed Abdel-Mohsen

Douglas Richman

Robert F Siliciano

Michel C Nussenzweig

Bonnie J Howell

Javier Martinez-Picado

Nicolas Chomont

Katharine J Bar

Xu G Yu

Mathias Lichterfeld

Jose Alcami

Daria Hazuda

Frederic Bushman

Janet D Siliciano

Michael R Betts

Adam M Spivak

Vicente Planelles

Beatrice H Hahn

Davey M Smith

Ya-Chi Ho

Maria J Buzon

Christian Gaebler

Mirko Paiardini

Qingsheng Li

Jacob D Estes

Thomas J Hope

Jay Kostman

Karam Mounzer

Marina Caskey

Lawrence Fox

Ian Frank

James L Riley

Pablo Tebas

Luis J Montaner

Affiliations

Soon will be listed here.

Abstract

Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will require a consensus on how best to measure the numbers of persistently infected cells with the potential to cause viral rebound after antiretroviral-therapy cessation in assessing the results of cure-directed strategies in vivo. Current measurements assess various aspects of the HIV provirus and its functionality and produce divergent results. Here, we provide recommendations from the BEAT-HIV Martin Delaney Collaboratory on which viral measurements should be prioritized in HIV-cure-directed clinical trials.

Citing Articles

Studies of young adults with perinatal HIV infection provide new clues for HIV cure.

Kuhn L, Thomas P AIDS. 2025; 39(4):457-458.

PMID: 40009204 PMC: 11867207. DOI: 10.1097/QAD.0000000000004107.

The challenges to detect, quantify, and characterize viral reservoirs in the current antiretroviral era.

Gutierrez H, Eugenin E NeuroImmune Pharm Ther. 2025; 3(3-4):211-219.

PMID: 39845128 PMC: 11751450. DOI: 10.1515/nipt-2024-0017.

Current methods for detecting and assessing HIV-1 antibody resistance.

Odidika S, Pirkl M, Lengauer T, Schommers P Front Immunol. 2025; 15():1443377.

PMID: 39835119 PMC: 11743526. DOI: 10.3389/fimmu.2024.1443377.

Evaluation and Real-world Experience of a Neutralization Susceptibility Screening Assay for Broadly Neutralizing Anti-HIV-1 Antibodies.

Pahus M, Zheng Y, Olefsky M, Gunst J, Tebas P, Taiwo B J Infect Dis. 2024; 231(2):424-434.

PMID: 39441137 PMC: 11841631. DOI: 10.1093/infdis/jiae486.

Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a "shock and kill" strategy for ART-free virological control: a phase II single-arm study.

Wu L, Zheng Z, Xun J, Liu L, Wang J, Zhang X Signal Transduct Target Ther. 2024; 9(1):231.

PMID: 39245675 PMC: 11381521. DOI: 10.1038/s41392-024-01943-9.

References

Chun T, Stuyver L, Mizell S, Ehler L, Mican J, Baseler M . Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997; 94(24):13193-7. PMC: 24285. DOI: 10.1073/pnas.94.24.13193. View

Zerbato J, McMahon D, Sobolewski M, Mellors J, Sluis-Cremer N . Naive CD4+ T Cells Harbor a Large Inducible Reservoir of Latent, Replication-competent Human Immunodeficiency Virus Type 1. Clin Infect Dis. 2019; 69(11):1919-1925. PMC: 6853701. DOI: 10.1093/cid/ciz108. View

Patro S, Brandt L, Bale M, Halvas E, Joseph K, Shao W . Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors. Proc Natl Acad Sci U S A. 2019; 116(51):25891-25899. PMC: 6925994. DOI: 10.1073/pnas.1910334116. View

Metcalf Pate K, Pohlmeyer C, Walker-Sperling V, Foote J, Najarro K, Cryer C . A Murine Viral Outgrowth Assay to Detect Residual HIV Type 1 in Patients With Undetectable Viral Loads. J Infect Dis. 2015; 212(9):1387-96. PMC: 4601916. DOI: 10.1093/infdis/jiv230. View

Zucchetto A, Virdone S, Taborelli M, Grande E, Camoni L, Pappagallo M . Non-AIDS-Defining Cancer Mortality: Emerging Patterns in the Late HAART Era. J Acquir Immune Defic Syndr. 2016; 73(2):190-6. DOI: 10.1097/QAI.0000000000001033. View

Chaillon A, Gianella S, Dellicour S, Rawlings S, Schlub T, de Oliveira M . HIV persists throughout deep tissues with repopulation from multiple anatomical sources. J Clin Invest. 2020; 130(4):1699-1712. PMC: 7108926. DOI: 10.1172/JCI134815. View

Plantin J, Massanella M, Chomont N . Inducible HIV RNA transcription assays to measure HIV persistence: pros and cons of a compromise. Retrovirology. 2018; 15(1):9. PMC: 5773137. DOI: 10.1186/s12977-017-0385-y. View

Chun T, Engel D, Berrey M, Shea T, Corey L, Fauci A . Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A. 1998; 95(15):8869-73. PMC: 21169. DOI: 10.1073/pnas.95.15.8869. View

Bullen C, Laird G, Durand C, Siliciano J, Siliciano R . New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med. 2014; 20(4):425-9. PMC: 3981911. DOI: 10.1038/nm.3489. View

10.

Tebas P, Stein D, Tang W, Frank I, Wang S, Lee G . Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014; 370(10):901-10. PMC: 4084652. DOI: 10.1056/NEJMoa1300662. View

11.

Baxter A, Niessl J, Fromentin R, Richard J, Porichis F, Massanella M . Multiparametric characterization of rare HIV-infected cells using an RNA-flow FISH technique. Nat Protoc. 2017; 12(10):2029-2049. PMC: 5697908. DOI: 10.1038/nprot.2017.079. View

12.

Cohen Y, Lorenzi J, Krassnig L, Barton J, Burke L, Pai J . Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. J Exp Med. 2018; 215(9):2311-2324. PMC: 6122972. DOI: 10.1084/jem.20180936. View

13.

Pasternak A, Lukashov V, Berkhout B . Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology. 2013; 10:41. PMC: 3637491. DOI: 10.1186/1742-4690-10-41. View

14.

Pollack R, Jones R, Pertea M, Bruner K, Martin A, Thomas A . Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. Cell Host Microbe. 2017; 21(4):494-506.e4. PMC: 5433942. DOI: 10.1016/j.chom.2017.03.008. View

15.

Pantaleo G, Graziosi C, Demarest J, Butini L, Montroni M, Fox C . HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993; 362(6418):355-8. DOI: 10.1038/362355a0. View

16.

Luzuriaga K, Gay H, Ziemniak C, Sanborn K, Somasundaran M, Rainwater-Lovett K . Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J Med. 2015; 372(8):786-8. PMC: 4440331. DOI: 10.1056/NEJMc1413931. View

17.

Cohn L, Silva I, Oliveira T, Rosales R, Parrish E, Learn G . HIV-1 integration landscape during latent and active infection. Cell. 2015; 160(3):420-32. PMC: 4371550. DOI: 10.1016/j.cell.2015.01.020. View

18.

Wong J, Hezareh M, Gunthard H, Havlir D, Ignacio C, Spina C . Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278(5341):1291-5. DOI: 10.1126/science.278.5341.1291. View

19.

Cesana D, Santoni de Sio F, Rudilosso L, Gallina P, Calabria A, Beretta S . HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells. Nat Commun. 2017; 8(1):498. PMC: 5591266. DOI: 10.1038/s41467-017-00609-1. View

20.

Wu G, Swanson M, Talla A, Graham D, Strizki J, Gorman D . HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. JCI Insight. 2017; 2(16). PMC: 5621903. DOI: 10.1172/jci.insight.92901. View